1
|
Fenaux H, Rafek R, Thouard, Decombe G, Vieux-Combe C, Hottelet C, Sulla P, Mouna L. Evaluation of the AltoStar AM16 system for the quantitation of AdV, CMV and HHV-6 DNA from clinical specimens. J Virol Methods 2024; 329:114982. [PMID: 38971380 DOI: 10.1016/j.jviromet.2024.114982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 06/05/2024] [Accepted: 06/11/2024] [Indexed: 07/08/2024]
Abstract
The vulnerability of immunocompromised patients to common or opportunistic viral infections is particularly high. The quantitation of viral load in clinical specimens is important for the diagnosis and management of the infection and reactivation in this patient population, particularly transplant recipients. As the new regulation "IVDR" regarding in vitro diagnosis methods is about to come into effect in France, diagnostic laboratories have to implement methods and systems compatible with this new regulation. Technical performance of the AltoStar® Adenovirus (AdV), Cytomegalovirus (CMV) and human Herpesvirus-6 (HHV-6) DNA PCR Kits 1.5 was assessed on the AltoStar Automation system AM16 using reference kits in 146 clinical samples. Overall agreement in clinical specimens was 87.5 % (28/32), 96.8 % (62/64), 100 % (22/22), 100 % (28/28) and 92.8 % (26/28) for AdV, CMV (WB samples and other matrices), HHV-6 A&B respectively. Quantitative results were highly correlated and estimated to be equivalent within a 0.057-0.648 log-amount difference.We found that altona kits on The AltoStar AM16 system are suitable for clinical monitoring of AdV, CMV and HHV-6 in immunocompromised hosts.
Collapse
Affiliation(s)
- H Fenaux
- AP-HP, hôpital Paul Brousse, Laboratoire de virologie, Villejuif 94800, France
| | - R Rafek
- AP-HP, hôpital Paul Brousse, Laboratoire de virologie, Villejuif 94800, France; Division of Virology, WHO Rubella National Reference Laboratory, Dept of Biology Genetics, Paul Brousse Hospital, Paris Saclay University Hospital, APHP, Villejuif, France
| | - Thouard
- AP-HP, hôpital Paul Brousse, Laboratoire de virologie, Villejuif 94800, France
| | - G Decombe
- AP-HP, hôpital Paul Brousse, Laboratoire de virologie, Villejuif 94800, France
| | - C Vieux-Combe
- AP-HP, hôpital Paul Brousse, Laboratoire de virologie, Villejuif 94800, France
| | - C Hottelet
- AP-HP, hôpital Paul Brousse, Laboratoire de virologie, Villejuif 94800, France
| | - Portet Sulla
- AP-HP, hôpital Paul Brousse, Laboratoire de virologie, Villejuif 94800, France; Division of Virology, WHO Rubella National Reference Laboratory, Dept of Biology Genetics, Paul Brousse Hospital, Paris Saclay University Hospital, APHP, Villejuif, France; Paris Saclay University, INSERM U1184, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| | - L Mouna
- AP-HP, hôpital Paul Brousse, Laboratoire de virologie, Villejuif 94800, France; Division of Virology, WHO Rubella National Reference Laboratory, Dept of Biology Genetics, Paul Brousse Hospital, Paris Saclay University Hospital, APHP, Villejuif, France.
| |
Collapse
|
2
|
Cabo J, Morimont L, Baudar J, Guldenpfennig M, Jacqmin H, Soleimani R, Lecompte T, Douxfils J, Mullier F. Variability among commercial batches of normal pooled plasma in lupus anticoagulant testing. Int J Lab Hematol 2023; 45:126-136. [PMID: 36222181 DOI: 10.1111/ijlh.13977] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Accepted: 09/15/2022] [Indexed: 01/18/2023]
Abstract
INTRODUCTION Lupus anticoagulant (LA) testing requires normal pooled plasma (NPP) in performing mixing studies and can be used for normalized ratios of clotting times (CTs). The aims were to demonstrate whether significant differences in clotting times between two batches of a same commercial NPP (CRYOcheck™) directly affect NPP-based cut-off values. METHODS Diluted Russell Viper venom time (DRVVT) and activated partial thromboplastin time (aPTT) were used for LA testing. Screening, mixing and confirm tests were performed with Stago® instruments and reagents. Two batches of commercial NPP (A1291 and A1301 from CRYOcheck™; frozen) were compared in the determination of cut-off values. Cut-off values were defined as 99th percentile values of 60 healthy donors and compared with Mann-Whitney U test. RESULTS Cut-off values obtained with the two NPP batches were significantly different for DRVVT (screen normalized ratio: 1.09 vs. 1.24, screen mix: 41.9 s vs. 38.9 s; index of circulating anticoagulant: 5.0 vs. 8.4; all had p-value <.001). On the contrary, no significant differences were observed for aPTT (screen normalized ratio: 1.32 vs. 1.34; p-value = .4068, screen mix: 37.8 s vs. 38.1 s; p-value = .1153) except for index of circulating anticoagulant: 9.6 versus 10.4 (p-value <.05). CONCLUSION This study demonstrates that differences between two commercial NPP batches produced by a same manufacturer influenced LA cut-off values used for mixing studies and normalized ratios. Adequate cut-off setting, taking into account NPP CTs, is important to provide accurate conclusion about the presence or absence of a LA and avoid potential clinical impact.
Collapse
Affiliation(s)
- Julien Cabo
- CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Université catholique de Louvain, Yvoir, Belgium
| | - Laure Morimont
- Département de pharmacie, Namur Thrombosis and Hemostasis Center (NTHC), Université de Namur, Namur, Belgium.,Qualiblood s.a., Namur, Belgium.,Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Université de Namur, Namur, Belgium
| | - Justine Baudar
- CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Université catholique de Louvain, Yvoir, Belgium
| | - Maité Guldenpfennig
- CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Université catholique de Louvain, Yvoir, Belgium
| | - Hugues Jacqmin
- CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Université catholique de Louvain, Yvoir, Belgium
| | - Reza Soleimani
- CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Université catholique de Louvain, Yvoir, Belgium
| | - Thomas Lecompte
- Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Université de Namur, Namur, Belgium.,Vascular Medicine Division and Regional Competence Centre for Rare Vascular and Systemic Autoimmune Diseases, Université de Lorraine, Nancy, France
| | - Jonathan Douxfils
- Département de pharmacie, Namur Thrombosis and Hemostasis Center (NTHC), Université de Namur, Namur, Belgium.,Qualiblood s.a., Namur, Belgium.,Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Université de Namur, Namur, Belgium
| | - François Mullier
- CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Université catholique de Louvain, Yvoir, Belgium.,Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Université de Namur, Namur, Belgium
| |
Collapse
|
3
|
Wauthier L, Favresse J, Hardy M, Douxfils J, Le Gal G, Roy P, van Es N, Ay C, ten Cate H, Lecompte T, Lippi G, Mullier F. D-dimer testing: A narrative review. Adv Clin Chem 2023. [DOI: 10.1016/bs.acc.2023.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/31/2023]
|
4
|
Bareille M, Hardy M, Chatelain B, Lecompte T, Mullier F. Laboratory evaluation of a new integrative assay to phenotype plasma fibrinolytic system. Thromb J 2022; 20:73. [PMID: 36471371 PMCID: PMC9724431 DOI: 10.1186/s12959-022-00435-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 11/15/2022] [Indexed: 12/07/2022] Open
Abstract
BACKGROUND There is currently no universal and standardized test available to phenotype plasma fibrinolytic system. AIMS Our main aims were to evaluate the performances of the 'global fibrinolysis capacity' assay (GFC) performed with the Lysis Timer® instrument, and to study the influence of some preanalytical conditions. METHOD Euglobulin clot lysis time (ECLT) and GFC were performed under several preanalytical conditions. RESULTS GFC showed satisfactory intra- and inter-run precision. Frozen controls and reagents showed stability over the studied period. There was no statistically significant difference between GFC assessed in plasma samples processed at 4 °C or at 20 °C. GFC assessed with frozen-thawed plasma samples was prolonged when compared to fresh samples (p = 0.014). The centrifugation scheme had no influence on PAI-1 activity levels, GFC and ECLT. Reference interval for GFC ranges from 29.3 (C I90% = 26.9-31.9) to 49.5 (90% CI = 45.9-52.2) minutes. In addition, a preliminary study in 40 healthy volunteers and 43 adult patients referred for investigation of a bleeding disorder was conducted to compare GFC and ECLT assays in their ability to classify samples with shortened or prolonged clot lysis times. Disagreements between ECLT and GFC were observed for 23 samples (out of 83), most of them minor. CONCLUSION GFC is suitable and convenient for a broad clinical use and can be performed with frozen-thawed plasma samples. Unlike ECLT, GFC is designed to take into account the balance between inhibitors and activators of the fibrinolytic system and could detect both hypo- and hyperfibrinolytic states. Whether it is as suitable as or even better than ECLT to detect a bleeding tendency due to a hyperactive fibrinolytic system deserves to be properly investigated.
Collapse
Affiliation(s)
- Marion Bareille
- grid.7942.80000 0001 2294 713XUniversité Catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Hematology Laboratory, Yvoir, Belgium
| | - Michael Hardy
- grid.7942.80000 0001 2294 713XUniversité Catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Department of Anesthesiology, Yvoir, Belgium
| | - Bernard Chatelain
- grid.7942.80000 0001 2294 713XUniversité Catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Hematology Laboratory, Yvoir, Belgium
| | - Thomas Lecompte
- grid.29172.3f0000 0001 2194 6418Université de Lorraine, Nancy, France ,grid.6520.10000 0001 2242 8479Université de Namur, Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium
| | - François Mullier
- grid.7942.80000 0001 2294 713XUniversité Catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Hematology Laboratory, Yvoir, Belgium
| |
Collapse
|
5
|
D-dimer Testing in Pulmonary Embolism with a Focus on Potential Pitfalls: A Narrative Review. Diagnostics (Basel) 2022; 12:diagnostics12112770. [PMID: 36428830 PMCID: PMC9689068 DOI: 10.3390/diagnostics12112770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Revised: 11/08/2022] [Accepted: 11/09/2022] [Indexed: 11/15/2022] Open
Abstract
D-dimer is a multifaceted biomarker of concomitant activation of coagulation and fibrinolysis, which is routinely used for ruling out pulmonary embolism (PE) and/or deep vein thrombosis (DVT) combined with a clinical pretest probability assessment. The intended use of the tests depends largely on the assay used, and local guidance should be applied. D-dimer testing may suffer from diagnostic errors occurring throughout the pre-analytical, analytical, and post-analytical phases of the testing process. This review aims to provide an overview of D-dimer testing and its value in diagnosing PE and discusses the variables that may impact the quality of its laboratory assessment.
Collapse
|